Compare KN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KN | ADPT |
|---|---|---|
| Founded | 1946 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2013 | 2019 |
| Metric | KN | ADPT |
|---|---|---|
| Price | $39.00 | $22.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $28.00 | $17.78 |
| AVG Volume (30 Days) | 1.1M | ★ 3.7M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.94 | 63.89 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $593,200,000.00 | $276,976,000.00 |
| Revenue This Year | $9.40 | $3.98 |
| Revenue Next Year | $6.98 | $22.72 |
| P/E Ratio | $332.82 | ★ N/A |
| Revenue Growth | 7.17 | ★ 54.77 |
| 52 Week Low | $19.28 | $9.96 |
| 52 Week High | $42.93 | $23.15 |
| Indicator | KN | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | N/A |
| Support Level | $33.53 | N/A |
| Resistance Level | $37.08 | N/A |
| Average True Range (ATR) | 1.20 | 0.00 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 58.73 | 0.00 |
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.